Literature DB >> 28804151

Mannitol Prescribing Practices With Cisplatin Before and After an Educational Newsletter Intervention.

Morgan Corbin1, John B Bossaer2.   

Abstract

Background: Mannitol has been used in the past for the prevention of cisplatin-induced nephrotoxicity. Studies on its efficacy have conflicting results. An educational newsletter was designed for local oncologists on the conflicting data of mannitol use in preventing cisplatin-induced nephrotoxicity. Purpose: The purpose of this study was to determine whether a pharmacist-created newsletter intervention led to changes in the mannitol prescribing practices of local oncologists.
Methods: A newsletter describing the paucity of evidence to support mannitol use to prevent cisplatin-induced nephrotoxicity was distributed via e-mail to local oncologists in October 2010. Mannitol prescribing rates were retrospectively evaluated before and after newsletter distribution. The Mann-Whitney U test was used to compare nonparametric continuous data. The chi-square test was used for nominal data. Descriptive statistics were performed for baseline demographics, and odds ratios were calculated for possible risk factors for acute kidney injury (AKI). The primary endpoint was a change in mean mannitol dose before and after the newsletter intervention. The secondary endpoint was the difference in the rate of AKI before and after the intervention. Data were collected for 67 patients with various malignancies.
Results: There was a difference in the average mannitol dose before and after newsletter intervention (P = .02). The rates of AKI before and after newsletter were similar.
Conclusion: A pharmacist-led newsletter intervention was associated with significantly decreased rates of mannitol usage after intervention.

Entities:  

Keywords:  cisplatin; mannitol; prescriber education; prescribing habits

Year:  2017        PMID: 28804151      PMCID: PMC5551635          DOI: 10.1177/0018578717715356

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  7 in total

1.  Pharmacist-led educational and error notification interventions on prescribing errors in family medicine clinic.

Authors:  Marquita B Winder; Jeremy L Johnson; Lourdes G Planas; Kimberly M Crosby; Brooke L Gildon; Linda A Oberst-Walsh
Journal:  J Am Pharm Assoc (2003)       Date:  2015 May-Jun

Review 2.  The role of mannitol as a nephroprotectant in patients receiving cisplatin therapy.

Authors:  Katherine P Morgan; Larry W Buie; Scott W Savage
Journal:  Ann Pharmacother       Date:  2012-01-31       Impact factor: 3.154

3.  Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial.

Authors:  Joseph T Santoso; Joseph A Lucci; Robert L Coleman; Ilona Schafer; Edward V Hannigan
Journal:  Cancer Chemother Pharmacol       Date:  2003-04-29       Impact factor: 3.333

4.  Rates of Renal Toxicity in Cancer Patients Receiving Cisplatin With and Without Mannitol.

Authors:  Katherine P Morgan; Anna C Snavely; Lucas S Wind; Larry W Buie; Juneko Grilley-Olson; Christine M Walko; Jared Weiss
Journal:  Ann Pharmacother       Date:  2014-04-28       Impact factor: 3.154

5.  Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a southwest oncology group study.

Authors:  M Al-Sarraf; W Fletcher; N Oishi; R Pugh; J S Hewlett; L Balducci; J McCracken; F Padilla
Journal:  Cancer Treat Rep       Date:  1982-01

6.  A comparison of the rates of cisplatin (cDDP)--induced nephrotoxicity associated with sodium loading or sodium loading with forced diuresis as a preventative measure.

Authors:  Lily Leu; David Baribeault
Journal:  J Oncol Pharm Pract       Date:  2009-09-16       Impact factor: 1.809

Review 7.  Cisplatin nephrotoxicity: a review.

Authors:  Xin Yao; Kessarin Panichpisal; Neil Kurtzman; Kenneth Nugent
Journal:  Am J Med Sci       Date:  2007-08       Impact factor: 2.378

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.